Motolimod (VTX-2337)

Description: Motolimod (also known as VTX-2337) is a novel, selective and potent small molecule agonist of the Toll-like receptor (TLR) 8 with EC50 of 100 nM, it displays > 50-fold selectivity over TLR7 and has potential immunostimulating and anticancer activities. Motolimod is currently under clinical development as an immunotherapy for multiple oncology indications such as ovarian cancer and squamous cell carcinoma of the head and neck. TLR8 is located in the endosome where it functions in the recognition of foreign nucleic acids from intracellular pathogens. TLR8 has emerged as a potential target for anticancer immunotherapies.

References: Clin Cancer Res. 2012 Jan 15; 18(2):499-509; J Clin Oncol 31, 2013 (suppl; abstr 3077).